+17.9%
ONDS vs GSK
+63.5%
-45.6%
-97.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.5% | -1.0% | +0.5% | -0.6% |
| 7D | -5.0% | -5.4% | +0.4% | -5.2% |
| 30D | -25.6% | -4.6% | -21.0% | -25.7% |
| 3M | -22.1% | -5.1% | -17.0% | -22.3% |
| 6M | -27.6% | -11.4% | -16.1% | -27.7% |
| YTD | -25.7% | +0.7% | -26.4% | -25.9% |
| 1Y | +30.4% | +23.0% | +7.4% | +27.7% |
| 3Y | +695.0% | +48.0% | +647.0% | +662.9% |
| 5Y | -2.2% | +48.2% | -50.4% | -6.9% |
| All | +17.9% | +63.5% | -45.6% | +11.8% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling